Nieuws nierkanker

balk2.jpg (42734 bytes)


Het eten van veel vlees bereid bij hoge temperaturen geeft hoger risico op nierkanker

Voeding met veel vlees kan leiden tot een verhoogd risico op niercelcarcinoom (RCC) door de inname van kankerverwekkende stoffen door bepaalde kooktechnieken, zoals barbecuen en bakken in de pan. Het MD Anderson Cancer Center van de Universtiteit aan Texas publiceerde online in het tijdschrift Cancer, de ontdekking door zijn onderzoekers dat mensen met bepaalde genetische mutaties gevoeliger zijn voor de schadelijke stoffen ontstaan tijdens het koken bij hoge temperaturen.

Lees verder

Lycopeen kan nierkanker voorkomen bij oudere vrouwen

Postmenopauzale vrouwen die regelmatig het natuurlijk antioxidant lycopeen consumeren verlagen gevoelig hun risico op een vorm van nierkanker. Lycopeen vindt men in voedingsmiddelen zoals tomaten, watermeloen en papaja.

Lees verder

Blootstelling aan zonlicht bij uitoefenen beroep en het risico op nierkanker bij mannen

Volgens een nieuw onderzoek (het grootste totnutoe op dit vlak), hebben mannen die tijdens de uitoefening van hun beroep veelvuldig aan zonlicht blootgesteld worden een lager risico op nierkanker dan mannen die binnen werken. Bij vrouwen vond het onderzoek deze relatie niet. Het onderzoek hield geen rekening met blootstelling aan zonlicht in de vrije tijd en trekt ook zelf niet de conclusie dat zonlicht nierkanker kan voorkomen.


Keimpe Wiersma

Study shows radiofrequency ablation highly effective in treating kidney tumors

Radiofrequency ablation, a relatively new, minimally invasive treatment, was 100 percent successful in eradicating small malignant kidney tumors in a study of more than 100 patients, report researchers from Wake Forest University Baptist Medical Center. Of 95 tumors that were smaller than 3.7 cm, all were completely eradicated by a single treatment, along with 14 of the larger tumors. Total success rate for all tumors was 93 percent.

Lees verder

Radiofrequency ablation highly effective in treating kidney tumors

A relatively new, minimally invasive treatment was 93 percent successful in eradicating malignant kidney tumors, according to a recent study conducted by researchers from Wake Forest University Baptist Medical Center in Winston-Salem, N.C.

Lees verder

Reactivating a critical gene lost in kidney cancer reduces tumor growth

Researchers at Mayo Clinic Jacksonville, have found that a key gene is often "silenced" in clear cell renal cell carcinoma, the most common type of kidney cancer, and when they restored that gene in human kidney cancer cells in culture and animal experiments, tumors stopped growing and many disappeared.

Lees verder

UC Davis discovery offers hope for treating kidney cancer

Kidney cancer is typically without symptoms until it has spread to other organs, when it is also the most difficult to treat. Newer chemotherapies show great promise for extending survival during later disease stages, but they can also be highly toxic. In one of the first discoveries of its kind, UC Davis Cancer Center researchers have identified ways to block a cancer gene's own repair mechanism and, in so doing, help make chemotherapy for kidney cancer more effective and better tolerated. The outcome is published in the current issue of Cancer Biology and Therapy. "Cancer cells are notorious in their ability to rapidly create copies of themselves. While the latest medications slow down that process, they do not tend to be curative and have many side effects," said Robert Weiss, a UC Davis professor of nephrology and chief of nephrology at the Sacramento VA Medical Center. "We wanted to find ways to help make chemotherapeutics as effective as possible at the lowest doses possible." Newer medications work by destabilizing cancer cells at the DNA level, which reduces their ability to replicate. Knowing that the p21 gene has an important role in restoring cancer cell DNA and potentially circumventing the benefits of those treatments, Weiss sought to identify compounds that could interrupt this pathway.

Lees verder

Stanford researchers find molecule that kills kidney cancer cells

Kidney cancer patients generally have one option for beating their disease: surgery to remove the organ. But that could change, thanks to a new molecule found by Stanford University School of Medicine researchers that kills kidney cancer cells.

Lees verder

Acrylamide May Hike RCC Risk

DIETARY INTAKE of acrylamide, a probable human carcinogen, may be associated with an increased risk of renal cell cancer, according to a report in the American Journal of Clinical Nutrition (2008;87:1428-1438).

Lees verder

NewYork-Presbyterian/Columbia leads research into robotic surgery for kidney cancer

Clinical research at NewYork-Presbyterian Hospital/Columbia University Medical Center is helping bring the advantages of robotic surgery, including reduced pain and quicker recovery, to kidney cancer patients.

Lees verder

How less can be more when treating some kidney cancers

A new Mayo Clinic study suggests that removing the entire kidney from younger patients with small kidney tumors may lead to decreased overall survival compared with an operation that removes the tumor but leaves the kidney intact.

Lees verder

Genetic breakthrough offers promise in tackling kidney tumors

Early tests show promising results for a new treatment for tuberous sclerosis, which can cause tumors in organs throughout the body. The UK study is led by Cardiff University's Institute of Medical Genetics, which was the first to identify the genes linked to the disease.

Lees verder

Scientists home in on the origins of childhood kidney cancer

Scientists at The Institute of Cancer Research have made significant progress in pinpointing two new risk factors associated with the most common childhood kidney cancer, known as Wilms tumour. The research published in Clinical Cancer Research today found that specific genetic changes in certain cells may cause childhood kidney cancer. Lead scientist, Dr Chris Jones at The Institute of Cancer Research says:“This discovery is a significant step forward and our findings will help locate those who are most at risk and hopefully lead to earlier diagnosis and better monitoring for patients.”The work is the first to study the entire genome (collection of genes that a person has) within these clusters of cells by analysing ‘DNA copy number changes’. “Around one per cent of children are born with clusters of embryonic cells in their kidneys left over from growing in the womb. One in a hundred of these children may then go on to develop a Wilms tumour. With the information from a study published today, doctors will be able to focus on which of these clusters pose the biggest threat of developing into cancer,” Dr Jones said.Around 70 children are diagnosed with Wilms tumour in the UK each year, the most common childhood renal cancer, affecting approximately one in every 10,000 children. Wilms Tumour is very treatable and most children can be cured. However, if both kidneys are affected the cure rate is lower and it is more difficult to preserve kidney function.

Lees verder

UK kidney cancer patients face toxic, out-dated treatments with little hope of change

The body that advises the UK Department of Health is likely to rule out four kidney cancer drugs on cost grounds, despite the fact that they represent the biggest breakthrough in treatment of the disease in the last 25 years. Professor Eisen of Cambridge University points out that without them there is no effective treatment for 90 percent of patients with the disease. The only drugs currently available are toxic, barely effective and outdated, he adds

Lees verder

A new pharmaceutical drug that halts progress of metastatic kidney cancer

Research has shown the efficacy of a pharmaceutical drug known as sunitinib which halts progress of metastatic kidney cancer. The work was published recently in the prestigious international medical journal, The New England Journal of Medicine and involved medical co-researchers from the Oncology Department of the University Hospital of Navarra, in collaboration with the Clinical Trials Area of the same Department.

To date the usual treatment for kidney cancer of a metastatic nature has been based solely on immunotherapy. In phase III of the research sunitinib was compared with interferon (a type of immunotherapy) in 750 patients with metastatic kidney cancer and it was shown that sunitinib is more efficient in halting the progress of the disease. 101 medical centres from all over the world took part in the research.

Given the short period of follow-up in the research, the effect of the treatment on survival rates could not be corroborated. Although, in general, the treatment is well tolerated, certain side effects can occur and have to be taken into consideration - hypothyroidism, high blood pressure and fatigue.

Metastatic kidney cancer is one of the cancer pathologies the treatment of which has made least progress in recent years. The usual treatment with immunotherapy had not shown clearly positive results in many patients. Sunitinib is one of the few pharmaceutical drugs that provide clear improvements in this type of cancer. The mechanism of functioning of sunitinib is in blocking the generation of new blood vessels. Tumours, in order to grow, need to develop blood vessels and this pharmaceutical drug impedes their growth, blocking a factor known as VEGF, and other similar ones, which stimulate vascular growth. The use of sunitinib in Spain is to be approved shortly for the treatment of kidney cancer with metastasis although, at the University Hospital, it has been employed with over 40 patients for the last two years, using clinical trials.

Lees verder

PET Imaging Identifies Aggressive Kidney Cancers that Require Surgery

A newly published study demonstrates that imaging with Positron Emission Tomography (PET) using a radiolabeled antibody accurately identifies whether a patient has clear cell renal carcinoma -- the most common and aggressive type of renal tumor -- and arms the urologist with crucial information that will help determine whether surgery is needed.

Lees verder

Sutent achieves first line EAU approval for kidney cancer

Sutent (sunitinib malate) has received a European Association of Urology recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma.

Lees verder

Cryoablation -- A New Treatment Option for Some Kidney Tumor Patients

Mayo Clinic researchers report that freezing kidney tumors through percutaneous cryoablation shows promise for patients who are not good candidates for surgery. Their early findings showing short-term success in more than 90 percent of selected patients are published in this month's issue of Radiology.

Lees verder

Glowing Dye Improves Cancer Removal in Kidney

A new way to provide clear images of cancerous tumors in the kidney during surgery promises to help physicians preserve as much kidney function as possible while still removing all the malignant tissue – a significant advance as doctors discover that saving as much healthy kidney tissue as possible is crucial for the future health of cancer patients.

Lees verder




View My Stats